9 unchanged sentences
First, the District Court granted Spectrum’s motion for summary judgment of noninfringement, holding that Spectrum’s saliva collection devices are not “kits for collecting and preserving a biological sample,” among other rulings.
−Removed: The Company has appealed the grant of summary judgment to the Court of Appeal on June 8, 2023.
−Removed: Second, the District Court denied Spectrum’s motion to amend its allegations of alleged antitrust violations, finding that if such an amendment were allowed, Spectrum’s claims would not survive a motion for summary judgment.
+Added: The Company appealed the grant of summary judgment to the Court of Appeals on June 8, 2023.
+Added: The appeal is pending, with oral argument expected in the second half of 2024.
+Added: Second, the Court denied Spectrum’s motion to supplement its allegations of alleged antitrust violations, finding that if such an amendment were allowed, Spectrum’s claims would not survive a motion for summary judgment.
Spectrum thereafter withdrew its antitrust and inequitable conduct counterclaims.
Spectrum did not appeal the District Court's denial of its motion to amend.
−Removed: Both parties have filed motions seeking sanctions in the District Court.
−Removed: Those motions remain pending.
−Removed: DNAG filed its opening appellate brief on September 28, 2023.
−Removed: Spectrum’s responsive appellate brief is due December 22, 2023.
−Removed: Oral argument in the appeal has not been scheduled.
−Removed: An inter partes review is currently pending before the PTO regarding the second asserted patent.
−Removed: Oral argument in the inter partes review is currently scheduled for November 14, 2023.
−Removed: On September 15, 2023, Spectrum filed a petition for inter partes review of a third patent, which DNAG did not assert in the District Court.
−Removed: An optional preliminary patent owner response is due in December 2023.
+Added: On February 7, 2024, the PTO issued a Final Written Decision regarding the second patent in the litigation, holding that claims 1, 3-8, 11 and 12 of U.S.
+Added: 11,002,646 B2 are unpatentable.
+Added: On March 8, 2024, the Company filed a Request for Rehearing by the Director of the PTO of the Final Written Decision.
+Added: On March 27, 2024, the Company's Request for Rehearing was denied.
+Added: The Company is considering its appellate options.
+Added: On September 15, 2023, Spectrum filed a separate petition for inter partes review of a third patent, which DNAG did not assert in the District Court.
+Added: On March 26, 2024, the PTO issued a Decision Granting Institution of Inter Partes Review and scheduled oral argument for January 14, 2025.
+Added: There have been no material changes to the risk factors disclosed in Item 1A, entitled “Risk Factors,” in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.